33 results about "Hyponatremia" patented technology

The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. The devices are designed to permit a state of normal urinary production to return quickly after the desmopressin flux is terminated.

The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.

The present invention relates to the cloning and characterization of a human serine / threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and / or in “macromolecular crowding” in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

Methods are provided for treating hyponatremia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and / or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor, optionally with a supply of carbohydrate, and / or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods.

The invention belongs to the field of anti heart failure drugs, and more specifically, relates to lixivaptan crystal form I and a preparation method and use of a pharmaceutical composition containing the lixivaptan crystal form I in preparation of drugs for treating hyponatremia. The lixivaptan crystal form I is prepared from 2-chloro-4-nitro benzoic acid as a starting material by esterification, hydrogenation reduction, acylation, hydrolysis, acyl chlorination and other reaction steps, and the prepared lixivaptan purity is 97.5%. The lixivaptan crystal form I and its powder are characterized by X ray diffraction diagrams, and the lixivaptan crystal form I is important for obtaining of compounds with high purity, very determined crystal form and good reproducibility due to good prospects for development and pharmaceutical value of the lixivaptan crystal form I.

The invention provides a uterine cavity perfusate recovery and metering, tissue specimen collection and pollution protection device. The uterine cavity perfusate recovery and metering, tissue specimen collection and pollution protection device comprises a funnel body, an upper patch and a lower patch connected with the upper patch. An operation opening is formed in the connecting position of the upper patch and the lower patch, the front edge of the funnel body is connected to the lower part of the operation opening, and a neck tying belt is arranged on the rear edge of the funnel body. Gum is arranged on the sides, away from the funnel body, of the upper patch and the lower patch, and a liquid storage bag with scales is arranged at a ventage of the funnel body. According to the uterine cavity perfusate recovery and metering, tissue specimen collection and pollution protection device, the absorption amount of the perfusate can be accurately obtained, and potential serious risks can be found and treated in time, so that the occurrence of body fluid overload and / or dilution hyponatremia caused by the fact that a large amount of perfusate is absorbed is prevented; operative complications are reduced, and important clinical significance for reducing medical accidents and protecting the life safety of a patient is achieved; and moreover, specimens can be effectively collected, specimen loss is prevented, perfusate splashing pollution is prevented, and high popularization value is achieved.

The present invention relates to the technical field of medicine, and specifically relates to a traditional Chinese medicine for treating hyperuricemia complicated with joint swelling. -30 parts, 15-25 parts of Verbaca, 15-25 parts of paeonol, 13-17 parts of Anemarrhena, 13-17 parts of Gotu Kola, 10-20 parts of Qingdai, 10-20 parts of Houttuynia cordata, 10 parts of Trichosanthes -20 parts, 15-19 parts of red peony, 12-18 parts of herb, 11-17 parts of Huanglian, 10-14 parts of Smilax, 10-14 parts of Polygonum cuspidatum, 10-14 parts of Panax notoginseng, 10-14 parts of black beans, Cyperus 11-17 parts, Fangfeng 10-18 parts, Artemisia annua 10-22 parts, Plantain 5-9 parts, Licorice 3-7 parts. A traditional Chinese medicine for treating hyperuricemia complicated with joint swelling of the present invention has scientific compatibility, and the components can coordinate to promote the discharge of uric acid, and can supplement sodium, potassium, calcium, zinc and other elements to prevent hyponatremia, Hypokalemia, hypocalcemia and other side effects; at the same time, it also has the effects of reducing swelling and pain, regulating qi and blood, removing dampness and turbidity, and treating arthritis.

The invention belongs to the field of anti-heart failure drugs, and more particularly relates to a lixivaptan crystal form II and a preparation method thereof, a drug composition containing the lixivaptan crystal form II, and a use of the lixivaptan crystal form II in preparation of hyponatremia treatment drugs. According to the present invention, 2-chloro-4-nitrobenzoic acid is adopted as a starting raw material, and esterification, hydrogenation reduction, acylation, hydrolysis, chlorination and other reaction steps are performed to prepare the lixivaptan crystal form II, wherein the purity of the obtained lixivaptan is 97.5%, and the lixivaptan crystal form II is characterized by the powder X-ray diffraction pattern; and due to the good development prospects and the pharmaceutical values of the compound, it is important to obtain the compound with characteristics of high purity, determined crystal form and good reproducibility.

The invention relates to the field of medicinal chemistry, and discloses a conivaptan-hydrochloride novel crystal form and a preparation method of the conivaptan-hydrochloride novel crystal form. The conivaptan-hydrochloride novel crystal form is single in crystal form, high in purity, good in stability, high in solubility and bioavailability, capable of restraining arginine vasopressin V1a and V2 receptors, and capable of being used for preparing medicine for treating hyponatremia. The preparation method of the conivaptan-hydrochloride novel crystal form is simple to operate, avoids complex and fussy crystallization processing conditions, enables solvents to be recycled, is low in production cost, and is suitable for industrial production. Products meet medicinal standards and good in stability.

The invention relates to a rehydration salt composition for preventing exertional heatstroke, which belongs to the technical field of combining traditional Chinese and western medicines. The rehydration salt composition is composed of the following raw materials in parts by weight: 0.585 parts of sodium chloride, 0.13 parts of potassium chloride, 0.0215 parts of calcium citrate malate, 0.9785 parts of anhydrous glucose, 0.06 parts of DL-malic acid, and sucralose 0.025 parts, 0.9785 parts of citric acid juice powder, 0.2 parts of Huoxiang extract and 0.1 part of tangerine peel extract. The invention has the following advantages: the product has a good taste, which is beneficial to the compliance of high-intensity training and replenishment of water and salt; after replenishing water and salt, the blood volume in the body increases, reduces the occurrence of hyponatremia, increases the amount of sweating, and increases the heat dissipation capacity of the body , to avoid heat stroke and heat stroke caused by excessive body temperature. Huoxiang, a traditional Chinese medicine, can prevent heatstroke, and tangerine peel can promote water absorption and reduce gastrointestinal discomfort.

The invention relates to a color function seasoning low-sodium liquid salt formula and a preparing method of color function seasoning low-sodium liquid salt. Low-sodium liquid salt mother liquor is used as main raw materials of the low-sodium liquid salt. The low-sodium liquid salt mother liquor comprises (according to the mass percent in the mother liquor salt content total quantity) 60%-80% of sodium chloride, 15%-30% of potassium chloride and 5%-15% of magnesium chloride. The low-sodium liquid salt further comprises a plant source function component with the adding quantity (according to the mass added into 100 mL of low-sodium liquid salt mother liquor) is 0.5%-10%. Optimization technologies such as mixing, homogenization, sterilization and filling are carried out, and color function seasoning low-sodium liquid salt products with function component activity being maintained to the maximum degree are prepared. A controllable-quantity liquid packaging container is used, the salt can be easily and evenly blended into food, the problem that solid salt is dissolved slowly, so that excessive adding or uneven dispersing may happen is solved, and accordingly eating is convenient and flexible. Compared with traditional solid salt production, during a production process of the liquid salt, a large amount of equipment needed for salt drying can be reduced, energy loss is lowered, and waste water discharging is lowered.

The invention discloses an acyl guanidine compound with a structure as shown in a formula I (See the specification) and pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compound. The invention also discloses a pharmaceutical composition taking the compound or pharmaceutically acceptable salt thereof as an active ingredient, and their application tothe prevention or treatment of diseases (such as hypertension, chronic congestive heart failure, antidiuretic hormone secretion disorder syndrome or hyponatremia caused by chronic heart failure / livercirrhosis / antidiuretic hormone secretion disorder) related to an arginine vasopressin V1a receptor, an arginine vasopressin V1b receptor and an arginine vasopressin V2 receptor.

The present invention provides a means which can appropriately control the balance between water and sodium in peritoneal dialysis therapies while avoiding adverse effects on the residual renal function and without causing hyponatremia. This peritoneal dialysate fluid contains 1.5 to 1.8 w / v% of glucose and 120 to 130 mEq / L of sodium, and is used alone one or two times a day. The peritoneal dialysate fluid is used in combination with another peritoneal dialysate fluid containing 1.35 to 2.5 w / v% of glucose and 132 to 135 mEq / L of sodium in peritoneal dialysis where the following steps are performed three to five times a day: injecting 1.5 to 2.0 L of a peritoneal dialysate fluid into the abdominal cavity of a subject; retaining the peritoneal dialysate fluid; and discharging the peritonealdialysate fluid.

The present invention involves novel urea compositions for oral administration, that are useful for treatment or management of hyponatremia. Also disclosed are novel methods of making the urea compositions.

The invention belongs to the field of low sodium treatment of aquatic product sauce and particularly relates to a process for electrodialysis low sodium treatment of aquatic product sauce. The process comprises a step (1) of filtering to-be-desalted feed liquid of the aquatic product sauce sequentially through a primary pipe type microfiltration device and a secondary pipe type microfiltration device to remove impurities such as suspended solids, and obtaining clear aquatic product sauce feed liquid, and causing the clear aquatic product sauce feed liquid to enter a first buffer adjusting tank; a step (2) of causing the clear aquatic product sauce in the first buffer adjusting tank to enter a first feed liquid tank, adjusting pH through a bipolar membrane electroosmosis device, adjusting the pH to an isoelectric point of the aquatic product sauce, obtaining the aquatic product sauce with the pH being at the isoelectric point, and causing the aquatic product sauce to enter a second buffer adjusting tank; a step (3) of causing the aquatic product sauce with the pH being at the isoelectric point in the second buffer adjusting tank, performing desalting treatment through the electroosmosis device, and obtaining a final product which is the low-salt low-sodium aquatic product sauce.